

# **EPL Limited**

October 05, 2023

| Facilities/Instruments                 | Amount (₹ crore) | Rating <sup>1</sup>         | Rating Action |
|--|------------------|-----------------------------|---------------|
| Long-term bank facilities              | 193.75           | CARE AA+; Stable            | Reaffirmed    |
| Long-term / Short-term bank facilities | 182.00           | CARE AA+; Stable / CARE A1+ | Reaffirmed    |
| Short-term bank facilities             | 5.00             | CARE A1+                    | Reaffirmed    |
| Non-convertible debentures             | -                | -                           | Withdrawn     |

Details of instruments/facilities in Annexure-1.

# **Rationale and key rating drivers**

The ratings assigned to the bank facilities of EPL Limited (hereinafter referred to as the company or EPL) continues to draw strength from the strong business risk profile driven by strong operating performance of the company during FY23 (refers to the period April 1 to March 31) and Q1FY24 amidst global challenging macroeconomic conditions, its ability to retain its established market position in the speciality packaging industry and healthy financial risk profile. The ratings continue to draw strength from EPL's strong business model encompassing a wide-spread geographical distribution network globally and a product portfolio for which the demand would continue to remain steady, given its essential nature of usage. The prospects of the industry also remain strong considering its diversified end usage (oral, beauty & cosmetics, pharma & health, food & nutrition, homecare etc.) and increasing preference of usage of laminated tubes for the manifold advantages it offers. Additionally, EPL is also benefitted from deep industry expertise of the Blackstone Group.

Nevertheless, the company faced several headwinds during the year from the lingering impact of COVID-19 in China, unprecedented volatility in the input costs and devaluation of Egyptian pound as a result of which the earnings before interest, taxes, depreciation, and amortisation (EBITDA) margins moderated to 15.65%. The input prices, which have recently been depicting a softening trend, are expected to stabilise the margins going forward. In Q1FY24, the EBITDA margin recovery has persisted. EPL reported EBITDA margin of 18.37%, an improvement of 284 basis points year-on-year. The future growth is expected to be driven by increasing contribution from margin-accretive personal care segment and commercialisation of a new project in Brazil. The debt metrics are also expected to remain comfortable despite a proposed debt-funded capex.

These strengths are, however, partially tempered due to lag effect in price pass through in respect of contracted customers and competitive intensity of the business. CARE Ratings Limited (CARE Ratings) notes that the company has entered Brazil, which is a new geography by setting up a greenfield project. Although capex execution risk is low considering EPL's track record in similar product line, its ability to establish its presence in a new geography would be monitorable.

CARE has withdrawn the rating assigned to Non-Convertible Debenture (ISIN - INE255A08AX9 and INE255A08AY7) as the same has been repaid in full and there is no outstanding against the same.

# Rating sensitivities: Factors likely to lead to rating actions

#### **Positive factors**

• Improvement in the scale of operations > ₹5,000 crore and profit before interest, lease rentals, depreciation and taxation (PBILDT) margins above 22%-25% on a sustainable basis.

- Ability to increase its global market share significantly to 50% or above in both the segments.
- Improvement in the overall gearing below 0.20x.

#### **Negative factors**

- Increase in the operating cycle above 120 days on a sustained basis.
- Decline in the PBILDT margin in the range of 12%-14% on a sustainable basis.
- Any large debt-funded organic or inorganic investment leading to deterioration in the overall gearing above 0.75x.

<sup>&</sup>lt;sup>1</sup>Complete definition of the ratings assigned are available at <u>www.careedge.in</u> and other CARE Ratings Ltd.'s publications



### Analytical approach:

The consolidated financials of EPL have been considered for analytical purposes owing to the financial and operational linkages between the company and its subsidiaries. The list of companies considered in consolidation as on March 31, 2023, is provided in **Annexure-6**.

### Outlook: Stable

The stable outlook reflects the sustenance of the improvement in the operating and financial risk profile of the company amidst healthy cash flow generation from operations and absence of any large debt-funded capex or acquisition plans in the medium term.

# Detailed description of the key rating drivers:

### Key strengths

**Presence of strong promoter group, supported by experienced management:** EPL's promoter is the Blackstone Group, which holds 51.53% stake in EPL as on June 30, 2023, and is one of the leading investment firms in the world, with an asset under management (AUM) of around USD 1 Trillion across sectors like private equity, real estate, hedge fund solutions and credit businesses. The group has an exposure in the packaging industry through acquisition of varied companies, such as the USA-based Graham Packaging, Owens-Illinois Inc, Ohio and China-based packaging firm, ShyaHsin. The onboarding of the Blackstone Group has also improved the financial flexibility of EPL and would also support enhancing EPL's global market share growth, both in the oral and the personal care segments. Mr. Anand Kripalu, who is the MD and CEO of EPL, has more than 30 years of experience in the fast-moving consumer goods (FMCG) industry, and is supported by a team of experienced professionals.

**Established global market position with a strong and well-diversified business & product profile:** EPL is in the business of manufacturing of multilayer plastic-laminated collapsible tubes, which are used in packaging of oral care, beauty and cosmetics, pharma, food, home and industrial products. It is a global player with their facilities located across multiple geographies divided into regional setups such as AMESA (Africa, Middle East & South Asia - India and Egypt), EAP (East Asia Pacific – China and Philippines), Americas (USA, Mexico, Brazil and Colombia) and Europe (UK, Poland, Russia and Germany). Erstwhile catering primarily to packaging in the oral care segment, EPL has gradually diversified to other personal care segments, such as Beauty & Cosmetics, Pharma & Health, Foods, etc.

In the oral care segment, EPL commands almost 37% of the market share globally and it is endeavouring to increase its share in the personal care segment where it foresees strong potential going forward. Although oral care, i.e., toothpaste forms a large part of the product portfolio, revenue dependency is mitigated by its essential day-to-day use nature and stable demand. EPL has long-standing relationship with reputed clientele globally.

**Steady performance during challenging business scenario:** FY23 continued to be challenging environment persisting for a major part of the year, impacting businesses globally. Nevertheless, EPL has delivered a steady performance reporting a y-o-y growth of 7.7% in total operating income (TOI) from FY22 to FY23. The growth was driven by AMESA, EUROPE and AMERICAS posting double digit revenue growth while EAP was subdued due to the pandemic. Also, AMESA was partly impacted by devaluation of Egyptian pound. Despite EPL achieving a y-o-y growth in the revenue, the higher RM costs in a volatile environment along with inflationary pressure impacted its profitability margins negatively. Following high input costs and high freight environment, the PBILDT margins of EPL resultantly declined by 115 bps from 16.80% in FY22 to 15.65% in FY23. To counter the increase in RM costs, EPL is undertaking price increase to the customers, accelerated cost savings, and improvement in procurement and production planning process. In Q1FY24, EPL reported EBITDA margin of 18.37%, an improvement of 284 basis points year-on-year.

**Margin accretive personal care segment and expansion in new geography to be key growth drivers:** Erstwhile catering only to the oral segment and few segments under personal care (mainly face care), EPL, over the past few years, has diversified into multiple sub-categories of personal care (viz., hair care, beauty cosmetics, pharma, food products, etc.). The personal care segment is a margin-accretive segment (requires more customisation and innovation in terms of printing, visual appeal, etc). The personal care segment has grown at a 15 % compounded annual growth rate (CAGR) over the last 12 years as compared with the relatively stable oral care segment, which has grown at a CAGR of 10.1% over the same period. EPL has expanded through a project in Brazil, which will open new categories to tap into. The offtake risk is low and the revenues are expected to ramp up from FY25 onwards.



**Debt metrics to remain comfortable:** Due to high input costs- and dividend payout, EPL's overall retained earnings (accretion to net worth) were lower in FY23 than the previous year. EPL also incurred higher financing cost in working capital due to supply chain disruption, RM price rise and incurred higher investment in capital expenditure to create future capabilities. Furthermore, there was increase in the term loan position from ₹ 440.60 crore in FY22 to ₹ 648.60 crore in FY23, majorly on account of increase in the term loan to fund the greenfield project in Brazil, along with term loans availed in other geographies. The above factors resulted in marginal decline in the debt metrics, nevertheless stood comfortable. EPL's overall gearing stood at 0.49x as on March 31, 2023 (P.Y. 0.46x).

However, despite higher debt, better negotiation and lower interest rates resulted in interest costs remaining under control. EPL has undertaken a capex of around ₹240 crore till June 2023 in Brazil in addition to regular growth capex in its existing facilities. However, with expected tempering of RM prices going forward, CARE Ratings expects working capital requirement to be comparatively lower. Along with scheduled term debt instalment repayment and expected higher cash accruals, EPL's debt metrics are expected to continue remaining comfortable going forward.

### Key weaknesses

**Exposure to raw material volatility and forex fluctuation:** The major RM consumed is polymer granules (linear low-density polyethylene [LLDPE], high-density polyethylene [HDPE], which is a derivative of crude oil and is highly sensitive to any volatility in crude oil prices, thereby exposing the operating performance of the company. To mitigate such risk, the long-term contracts executed with the company's oral care customers have inbuilt a RM cost escalation pass through clause albeit with a lag of three months. The global nature of operations exposes the company's margins to fluctuations in foreign exchange rates. Loss on account of exchange difference was ₹ 21.3 crore for FY23 (P.Y. ₹ 2.2 crore) which was mainly due to 36% depreciation of Egyptian pound. The forex risk is mitigated by minimising cross currency transactions, using natural hedge and the use of currency forwards.

**Moderate competition from unorganised segment:** EPL faces competition from unorganised players due to low entry barriers in the industry. However, EPL's scale, technology, integrated manufacturing process, innovation capability and operational efficiencies are factors which further strengthen its competitive advantage and ability to withstand competition.

# Liquidity: Strong

As on March 31, 2023, the company's cash and cash equivalents stood at around ₹ 240 crore on a consolidated basis (P.Y. ₹ 188 crore). The company's liquidity is also supported by a current ratio above unity. EPL has scheduled debt repayment of ₹ 214 crores including lease liability and NCD already paid in FY24 and it is expected to generate gross cash accruals (GCA) of around ₹ 450 to 500 crore annually which are sufficient to meet debt repayment. Company has access to capital market avenues and good market reputation to raise capital or refinance high-cost debt if need arises. On a standalone basis, the company's fund - based working capital limit utilisation stands low thus providing additional liquidity cushion. Working capital borrowings are largely in overseas subsidiaries.

# Environment, social, and governance (ESG) risks

| Particulars   | Risk factors   |
|---------------|--|
| Environmental | The company faces environmental risks related to compliance with that are inherent to the        |
|               | packaging industry as a result of polymer usage.   |
|               | By focusing on recyclable products, the company is driving more and more sustainable solutions,  |
|               | and is focussed on improving its manufacturing and process efficiencies.                         |
| Social        | EPL undertakes its welfare activities directly and through its CSR activities and spent around ₹ |
|               | 3.29 crores in FY23. The company has focused primarily on upgradation of educational facilities, |
|               | educational assistance to downtrodden and economically deprived students of the society,         |
|               | promoting healthcare including sanitation and preventive healthcare, employment enhancing        |
|               | vocation skills amongst industrial workers etc.  |
| Governance    | Neither governance issues as per auditor's report nor any qualified opinion.                     |



# Applicable criteria

Policy on default recognition <u>Consolidation</u> <u>Financial Ratios – Non financial Sector</u> <u>Liquidity Analysis of Non-financial sector entities</u> <u>Rating Outlook and Credit Watch</u> <u>Short Term Instruments</u> <u>Manufacturing Companies</u> <u>Policy on Withdrawal of Ratings</u>

# About the company and industry

### Industry classification

| Macro economic<br>Indicator | Sector        | Industry            | Basic Industry |
|-----------------------------|---------------|---------------------|----------------|
| Industrials                 | Capital Goods | Industrial Products | Packaging      |

EPL Limited, founded in 1982, is a global manufacturer of laminated plastic tubes and laminates. Its products are extensively used in the packaging of products across categories, such as oral care, beauty and cosmetics, pharma and health, foods, and home care. EPL is one of the world's largest manufacturers holding oral care market share of around one-third in volume terms globally with business in four geographical segments, namely, Americas (with operations in the USA, Brazil, Mexico, and Colombia), Europe (with operations in the UK, Germany, Poland), AMESA (Africa, Middle East & South Asia – with operations in Egypt and India) and EAP (East Asia Pacific, with operations in China and Philippines). EPL functions through 20 facilities in 10 countries, selling approximately 8 billion tubes on an annual basis.

| Brief Financials (₹ crore) | March 31, 2022 (A) | March 31, 2023 (A) | Q1FY24(UA) |
|----------------------------|--------------------|--------------------|------------|
| Total operating income     | 3,432.80           | 3,694.10           | 910.20     |
| PBILDT                     | 578.30             | 578.20             | 169.00     |
| РАТ                        | 221.30             | 230.70             | 55.60      |
| Overall gearing (times)    | 0.46               | 0.49               | -          |
| Interest coverage (times)  | 14.31              | 8.58               | 7.19       |

A: Audited UA: Unaudited; Note: `the above results are latest financial results available'

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Please refer Annexure-2

**Covenants of rated instrument / facility:** Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5



# Annexure-1: Details of instruments/facilities

| Name of the<br>Instrument                       | ISIN                         | Date of<br>Issuance<br>(DD-MM-<br>YYYY) | Coupon<br>Rate (%) | Maturity<br>Date (DD-<br>MM-YYYY) | Size of the<br>Issue<br>(₹ crore) | Rating<br>Assigned<br>along with<br>Rating<br>Outlook |
|---|------------------------------|---|--------------------|-----------------------------------|-----------------------------------|---|
| Debentures-<br>Non<br>Convertible<br>Debentures | INE255A08AX9<br>INE255A08AY7 | 14/12/2020                              | 6.50%              | 14/06/2023                        | 0.00                              | Withdrawn   |
| Fund-based -<br>LT-Term Loan                    |                              | -                                       | -                  | 08/09/2027                        | 193.75                            | CARE AA+;<br>Stable                                   |
| Fund-based-<br>Short Term                       |                              | -                                       | -                  | -                                 | 5.00                              | CARE A1+  |
| Fund-<br>based/Non-<br>fund-based-<br>LT/ST     |                              | -                                       | -                  | -                                 | 40.00                             | CARE AA+;<br>Stable / CARE<br>A1+                     |
| Fund-<br>based/Non-<br>fund-based-<br>LT/ST     |                              | -                                       | -                  | -                                 | 30.00                             | CARE AA+;<br>Stable / CARE<br>A1+                     |
| Fund-<br>based/Non-<br>fund-based-<br>LT/ST     |                              | -                                       | -                  | -                                 | 112.00                            | CARE AA+;<br>Stable / CARE<br>A1+                     |

# Annexure-2: Rating history for the last three years

|            |  | Current Ratings |                                    | Rating History                          |   |  |   |   |
|------------|--|-----------------|------------------------------------|---|---|--|---|---|
| Sr.<br>No. | Name of the<br>Instrument/Bank<br>Facilities | Туре            | Amount<br>Outstanding<br>(₹ crore) | Rating                                  | Date(s)<br>and<br>Rating(s)<br>assigned<br>in 2023-<br>2024 | Date(s)<br>and<br>Rating(s)<br>assigned<br>in 2022-<br>2023                                | Date(s)<br>and<br>Rating(s)<br>assigned in<br>2021-2022 | Date(s)<br>and<br>Rating(s)<br>assigned in<br>2020-2021 |
| 1          | Fund-based - LT-<br>Term Loan                | LT              | 193.75                             | CARE<br>AA+;<br>Stable                  | -   | 1)CARE<br>AA+;<br>Stable<br>(06-Oct-<br>22)<br>2)CARE<br>AA+;<br>Stable<br>(30-Aug-<br>22) | 1)CARE AA;<br>Stable<br>(07-Sep-21)                     | 1)CARE AA;<br>Stable<br>(11-Sep-20)                     |
| 2          | Fund-based/Non-<br>fund-based-LT/ST          | LT/ST*          | 30.00                              | CARE<br>AA+;<br>Stable<br>/ CARE<br>A1+ | -   | 1)CARE<br>AA+;<br>Stable /<br>CARE A1+<br>(06-Oct-<br>22)                                  | 1)CARE AA;<br>Stable /<br>CARE A1+<br>(07-Sep-21)       | 1)CARE A1+<br>(11-Sep-20)                               |



|            |  |        | Current Rating                     | s                                       | Rating History  |  |   |   |
|------------|--|--------|------------------------------------|---|---|--|---|---|
| Sr.<br>No. | Name of the<br>Instrument/Bank<br>Facilities | Туре   | Amount<br>Outstanding<br>(₹ crore) | Rating                                  | Date(s)<br>and<br>Rating(s)<br>assigned<br>in 2023-<br>2024 | Date(s)<br>and<br>Rating(s)<br>assigned<br>in 2022-<br>2023  | Date(s)<br>and<br>Rating(s)<br>assigned in<br>2021-2022 | Date(s)<br>and<br>Rating(s)<br>assigned in<br>2020-2021 |
|            |  |        |                                    |   |   | 2)CARE<br>AA+;<br>Stable /<br>CARE A1+<br>(30-Aug-<br>22)  |   |   |
| 3          | Fund-based/Non-<br>fund-based-LT/ST          | LT/ST* | 112.00                             | CARE<br>AA+;<br>Stable<br>/ CARE<br>A1+ | -   | 1)CARE<br>AA+;<br>Stable /<br>CARE A1+<br>(06-Oct-<br>22)<br>2)CARE<br>AA+;<br>Stable /<br>CARE A1+<br>(30-Aug-<br>22) | 1)CARE AA;<br>Stable /<br>CARE A1+<br>(07-Sep-21)       | 1)CARE AA;<br>Stable<br>(11-Sep-20)                     |
| 4          | Non-fund-based -<br>LT-BG/LC                 | LT     | -                                  | -                                       | -   | -  | -   | 1)Withdrawn<br>(11-Sep-20)                              |
| 5          | Fund-based-Short<br>Term                     | ST     | 5.00                               | CARE<br>A1+                             | -   | 1)CARE<br>A1+<br>(06-Oct-<br>22)<br>2)CARE<br>A1+<br>(30-Aug-<br>22)   | 1)CARE A1+<br>(07-Sep-21)                               | 1)CARE A1+<br>(11-Sep-20)                               |
| 6          | Fund-based/Non-<br>fund-based-LT/ST          | LT/ST* | 40.00                              | CARE<br>AA+;<br>Stable<br>/ CARE<br>A1+ | _   | 1)CARE<br>AA+;<br>Stable /<br>CARE A1+<br>(06-Oct-<br>22)<br>2)CARE<br>AA+;<br>Stable /<br>CARE A1+<br>(30-Aug-<br>22) | 1)CARE AA;<br>Stable /<br>CARE A1+<br>(07-Sep-21)       | 1)CARE AA;<br>Stable /<br>CARE A1+<br>(11-Sep-20)       |
| 7          | Debentures-Non<br>Convertible<br>Debentures  | LT     | -                                  | -                                       | -   | -  | 1)Withdrawn<br>(07-Sep-21)                              | 1)CARE AA;<br>Stable<br>(11-Sep-20)                     |



|            |  | Current Ratings |                                    | Rating History |   |  |   |   |
|------------|--|-----------------|------------------------------------|----------------|---|--|---|---|
| Sr.<br>No. | Name of the<br>Instrument/Bank<br>Facilities | Туре            | Amount<br>Outstanding<br>(₹ crore) | Rating         | Date(s)<br>and<br>Rating(s)<br>assigned<br>in 2023-<br>2024 | Date(s)<br>and<br>Rating(s)<br>assigned<br>in 2022-<br>2023                                | Date(s)<br>and<br>Rating(s)<br>assigned in<br>2021-2022 | Date(s)<br>and<br>Rating(s)<br>assigned in<br>2020-2021 |
| 8          | Debentures-Non<br>Convertible<br>Debentures  | LT              | -                                  | -              | -   | 1)CARE<br>AA+;<br>Stable<br>(06-Oct-<br>22)<br>2)CARE<br>AA+;<br>Stable<br>(30-Aug-<br>22) | 1)CARE AA;<br>Stable<br>(07-Sep-21)                     | 1)CARE AA;<br>Stable<br>(04-Dec-20)                     |

\*Long term/Short term.

# Annexure-3: Detailed explanation of covenants of the rated instruments/facilities

| Name of the Instrument                        | Detailed Explanation                                      |  |  |
|---|---|--|--|
| A. Financial covenants                        |   |  |  |
| Debt service coverage ratio                   | Should not be below 1.20x                                 |  |  |
| Total debt/PBILDT                             | Should not exceed 3.0x                                    |  |  |
|   |   |  |  |
| B. Non-financial covenants/Promoter covenants | The promoter group shall hold minimum 51% equity stake in |  |  |
|   | the company.  |  |  |
|   |   |  |  |

# Annexure-4: Complexity level of the various instruments rated.

| Sr. No. | Name of the Instrument                   | Complexity Level |
|---------|--|------------------|
| 1       | Debentures-Non Convertible<br>Debentures | Simple           |
| 2       | Fund-based - LT-Term Loan                | Simple           |
| 3       | Fund-based-Short Term                    | Simple           |
| 4       | Fund-based/Non-fund-based-LT/ST          | Simple           |

# **Annexure-5: Lender details**

To view the lender wise details of bank facilities please click here

# Annexure 6:

| Particulars of subsidiaries as on March 31, 2023<br>(March 31, 2022) | % holding<br>(direct + indirect) | Country of Incorporation |
|--|----------------------------------|--------------------------|
| Direct subsidiaries  |                                  |                          |
| Arista Tubes, Inc.   | 100% (100%)                      | USA                      |
| Lamitube Technologies (Cyprus) Ltd                                   | 100% (100%)                      | Cyprus                   |
| Lamitube Technologies Ltd  | 100% (100%)                      | Mauritius                |
| Creative Stylo Packs Pvt Ltd #                                       | Nil (72.46%)                     | India                    |



| Particulars of subsidiaries as on March 31, 2023<br>(March 31, 2022) | % holding<br>(direct + indirect) | Country of Incorporation |
|--|----------------------------------|--------------------------|
| EPL Brasil LTDA@   | 100%(Nil)                        | Brazil                   |
| Step-down subsidiaries   |                                  |                          |
| EPL MISR for Advanced Packaging S.A.E                                | 75% (75%)                        | Egypt                    |
| EPL Packaging (Guangzhou) Ltd  | 100% (100%)                      | China                    |
| EPL Packaging (Jiangsu) Ltd  | 100% (100%)                      | China                    |
| EPL Propack Philippines, Inc.  | 100% (100%)                      | Philippines              |
| MTL DE Panama, SA  | 100% (100%)                      | Panama                   |
| EPL Propack UK Limited   | 100% (100%)                      | United Kingdom           |
| EPL Deutschland Gmbh& Co. KG   | 100% (100%)                      | Germany                  |
| EPL Deutschland Management GMBH                                      | 100% (100%)                      | Germany                  |
| EPL Propack de Mexico, SA de CV                                      | 100% (100%)                      | Mexico                   |
| Tubopack de Columbia S.A.S*  | Nil (100%)                       | Colombia                 |
| Laminate Packaging Columbia S.A.S.                                   | 100% (100%)                      | Colombia                 |
| EPL Propack LLC  | 100% (100%)                      | Russia                   |
| EPL Poland Sp z.o.o  | 100% (100%)                      | Poland                   |
| EPL America, LLC   | 100% (100%)                      | USA                      |
| Associate  |                                  |                          |
| P.T. Lamipak Primula   | 30%                              | Indonesia                |

# Amalgamated with Holding Company on September 16, 2022.

\* Completed voluntary dissolution process on June 30, 2022.

@ Incorporated on May 25, 2022.

**Note on the complexity levels of the rated instruments:** CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.



#### Contact us

| Media Contact                     | Analytical Contacts                |
|-----------------------------------|------------------------------------|
| Mradul Mishra                     | Ranjan Sharma                      |
| Director                          | Senior Director                    |
| CARE Ratings Limited              | CARE Ratings Limited               |
| Phone: +91-22-6754 3596           | Phone: + +91 - 22 - 6754 3453      |
| E-mail: mradul.mishra@careedge.in | E-mail: Ranjan.Sharma@careedge.in  |
| Relationship Contact              | Pulkit Agarwal                     |
|                                   | Director                           |
| Saikat Roy                        | CARE Ratings Limited               |
| Senior Director                   | Phone: 91 - 22 - 6754 3505         |
| CARE Ratings Limited              | E-mail: pulkit.agarwal@careedge.in |
| Phone: +91-22-67543404            |                                    |
| E-mail: saikat.roy@careedge.in    | Arti Roy                           |
|                                   | Associate Director                 |
|                                   | CARE Ratings Limited               |
|                                   | Phone: 91 - 22 - 6754 3657         |
|                                   | E-mail: arti.roy@careedge.in       |
|                                   |                                    |
|                                   |                                    |
|                                   |                                    |

#### About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

#### **Disclaimer:**

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

For the detailed Rationale Report and subscription information, please visit <u>www.careedge.in</u>